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Abstract
Arylamine N-acetyltransferase-1 (NAT1) is an enzyme that catalyzes the biotransformation of arylamine and hydrazine
substrates. It also has a role in the catabolism of the folate metabolite p-aminobenzoyl glutamate. Recent bioinformatics
studies have correlated NAT1 expression with various cancer subtypes. However, a direct role for NAT1 in cell biology has
not been established. In this study, we have knocked down NAT1 in the colon adenocarcinoma cell-line HT-29 and found a
marked change in cell morphology that was accompanied by an increase in cell-cell contact growth inhibition and a loss of
cell viability at confluence. NAT1 knock-down also led to attenuation in anchorage independent growth in soft agar. Loss of
NAT1 led to the up-regulation of E-cadherin mRNA and protein levels. This change in E-cadherin was not attributed to RNAi
off-target effects and was also observed in the prostate cancer cell-line 22Rv1. In vivo, NAT1 knock-down cells grew with a
longer doubling time compared to cells stably transfected with a scrambled RNAi or to parental HT-29 cells. This study has
shown that NAT1 affects cell growth and morphology. In addition, it suggests that NAT1 may be a novel drug target for
cancer therapeutics.
Citation: Tiang JM, Butcher NJ, Cullinane C, Humbert PO, Minchin RF (2011) RNAi-Mediated Knock-Down of Arylamine N-acetyltransferase-1 Expression Induces
E-cadherin Up-Regulation and Cell-Cell Contact Growth Inhibition. PLoS ONE 6(2): e17031. doi:10.1371/journal.pone.0017031
Editor: Austin Cooney, Baylor College of Medicine, United States of America
Received October 21, 2010; Accepted January 9, 2011; Published February 9, 2011
Copyright:  2011 Tiang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Health and Medical Research Foundation, Australia (NHMRC 569695). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: n.butcher@uq.edu.au.
Introduction
Human arylamine N-acetyltransferase-1 (NAT1; EC 2.3.1.5) is
a well characterized enzyme that catalyzes the transfer of an acetyl
group from acetyl coenzyme A to the amino group of arylamine
and/or hydrazine compounds [1]. NAT1 is genetically polymor-
phic and different alleles express proteins with altered catalytic
activity [2]. Although NAT1 has a widespread tissue distribution,
the folate catabolite p-aminobenzyolglutamate is the only known
endogenous substrate [3]. NAT1 gene expression involves 2
promoters that generate at least 9 different transcripts, all with an
identical protein coding sequence. The NAT1 gene is inducible
with androgens [4] and stability of the NAT1 protein is affected by
substrates, which enhance poly-ubiquitination and degradation
[5,6].
In human breast cancer samples, NAT1 mRNA levels have
been shown to cluster with a group of genes that included the
estrogen receptor, being highest in luminal-type carcinomas and
lowest in basal-like carcinomas [7,8,9]. The selective expression of
NAT1 in tumor subtypes is not confined to breast cancer. In a
gene profiling study, Lapointe and coworkers identified 3 separate
prostate cancer subtypes, each with markedly different levels of
NAT1 expression [10]. NAT1 mRNA levels also appear to be up-
regulated in p53 wild-type tumors compared to p53 loss-of-
function tumors [11].
When NAT1 was over-expressed in the immortalized breast
epithelial cell line HB4a, the resulting cells showed an increased
proliferative capacity and the ability to grow in low serum
conditions [8]. Moreover, the cells showed enhanced resistance to
the cytotoxic drug etoposide. These studies implied that NAT1
may play a role in cell growth and survival, although no
underlying mechanism has been proposed. The purpose of the
present study was to investigate the effects of altered NAT1
expression on cell proliferation and to characterize any changes in
phenotype associated with NAT1 activity. Previously, we have
generated several cell lines that over-express NAT1 [5]. However,
we observed no changes in proliferation or cell morphology. Here,
we report the effects of silencing NAT1 using shRNA. For these
studies, we chose the well-characterized human colon adenocar-
cinoma cell line HT-29 because these cells carry only one copy of
the NAT1 gene due to a deletion at 8p21-22 [12]. Normally, HT-
29 cells express NAT1 at levels approximately half that seen in
other cell lines [13]. These cells also carry a truncated APC gene
[14] and mutations in the p53 gene [15]. Using HT-29 cells stably
expressing shRNA targeting NAT1 mRNA, we have compared
the growth kinetics and phenotypic changes associated with altered
NAT1 expression.
Materials and Methods
Cell culture
The HT-29 colon adenocarcinoma cell line was obtained from
the American Type Culture Collection (Manassas, VA, USA).
Cells were cultured in RPMI 1640 supplemented with 5% fetal
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a humidified atmosphere of 5% CO2 in air.
Cell transfection
The Suresilencing
TM shRNA plasmid targeting the human
NAT1 open reading frame was purchased from SuperArray,
Bioscience Corporation, MD, USA. Transfection was performed
using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocol. The shRNA in controls
is a scrambled sequence that does not have homology to any
human gene. Stable cell lines were selected with 1 mg/ml G418.
To generate shRNA 3.2+NAT1 cells, linearized pEF-Neo plasmid
containing NAT1 was co-transfected with pTK-HYG and stable
cell lines were selected with 0.5 mg/ml Hygromycin.
NAT1 activity assay
Cells were washed with PBS, resuspended in lysis buffer
(20 mM Tris, pH 7.4, 1 mM EDTA, and 1 mM DTT) and lysed
by sonication. Cell lysates were then centrifuged at 14,0006g,4 uC
for 10 min and the supernatant assayed for NAT1 activity by high
performance liquid chromatography as previously described [6].
Protein concentrations were determined by the method of
Bradford [16].
Cell proliferation assay
Cells were plated at a density of 5,000 cells/well in 96-well plates.
After 24 h, growth rate was measured using the CellTiter96H
AQueous Non-Radioactive Cell Proliferation Assay kit (Promega,
Madison, WI, USA) over 5–6 days following the manufacturer’s
instructions.Theconversion of MTSinto formazanwasmeasured at
540 nm with a micro-plate reader (Bio-Rad, Hercules, CA, USA).
Cell viability
Plated cells at day 4 were stained with 1 mg/ml propidium
iodide on ice for 20 min and analyzed by FACSCanto
TM flow
cytometry. The dead cells population was determined as the
percentage of propidium iodide stained cells.
Transmission Electron Microscopy
HT-29 cells were grown on dishes and fixed with 3% glutaralde-
hyde (ProSciTech, Townsville, Australia) in 0.1 M phosphate buffer
a n dt h e np o s t - f i x e dw i t h1 %o s m i u mt e t r o x i d e( P r o S c i T e c h ) .
Following dehydration in an ascending series of ethanol, specimens
were embedded in a thin layer of LX 112 resin (Ladd Research,
Williston, Vermont, USA). The resin was polymerized at 60uCf o r
48 h in an oven before ultrathin sections were stained with uranyl
acetate (SPI, West Chester, Pennsylvania, USA) and lead citrate prior
to imaging. Samples were cut to reveal both transverse and
longitudinal sections. Transmission electron microscopy images were
taken using a JEOL 1010 (JEOL, Tokyo, Japan) fitted with a SIS
Megaview III digital camera and operated at 80 kV.
Anchorage-independent colony formation
Cells were suspended in 2 ml complete media containing 0.3%
agar (Sigma-aldrich, St. Louis, MO, USA) and seeded in to wells
(3,000 cells/well) layered with 0.6% base agar. 10–14 days after
seeding, colonies were stained with 0.005% crystal violet, photo-
graphed and counted using Quantity One Software (Bio-Rad). The
size of colonies was determined using Adobe Photoshop 7.
Western blot analysis
Cells were lysed in SDS reducing buffer and electrophoresed on
12% polyacrylamide gels, transferred to nitrocellulose membranes,
and immunoblotted overnight at 4uC with either anti-E-cadherin
(HECD-1, Abcam, Cambridge, UK), anti-SNAIL (sc-28199,
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-SLUG
(ab27568, Abcam, Cambridge, UK), or anti-Twist (sc-15393,
Santa Cruz Biotechnology). Membranes were washed and then
incubated with horseradish peroxidase conjugated secondary
antibodies for 1 h, washed, and then levels of protein detected
using Immun-Star
TM HRP Chemiluminescent kit (Bio-Rad).
Tubulin immunoblot using DM1A antibody (Calbiochem, Darm-
stadt, Germany) was used as the loading control.
Immunocytochemistry
Cells that had been grown on coverslips were chilled on ice for
15 min, washed with cold PBS, and then fixed with 2%
formaldehyde containing 0.1% Triton-X on ice for 30 min. Cells
were blocked with 1% BSA at room temperature for 1 h. For F-
actin staining, cells were incubated with Alexa Fluor 647
conjugated phalloidin (Molecular Probes, USA) for 1 h and
samples were mounted using VectorshieldH mounting medium
with DAPI (Vector Laboratories, Inc., Burlingame, CA, USA). For
E-cadherin immunocytochemistry, after blocking with BSA, cells
were blotted with E-cadherin antibody (HECD-1, Abcam)
overnight at 4uC. Cells were then washed and probed with Alexa
Fluor 488H conjugated secondary antibody (Molecular Probes) for
1 h prior to mounting with VectorshieldH mounting medium with
DAPI (Vector Laboratories, Inc.,). Slides were visualized using an
Olympus BX61 confocal microscope.
Extraction of total RNA and cDNA synthesis
Exponentially growing cells were washed with PBS and total
RNA was extracted using TRIzol reagent (Invitrogen) according
to manufacturer’s instructions. RNA was resuspended in RNase-
free water and reverse transcribed using Superscript II Reverse
Transcriptase (Invitrogen) and oligo(dT)15 primer (Promega).
Quantification of mRNA by real-time PCR
Expression levels of mRNA were determined using an iCycler
IQ Real-time PCR Detection System (Bio-Rad). For endogenous
NAT1 mRNA, first-strand cDNA was amplified using forward
primer 59- TCTAGTTCCTGGTT-GCCGGCTGAAATAACC-
39 and reverse primer 59-CTCAAAGGGAACCG-CGGGG-
ATCTGGTGTTG-39. For E-cadherin mRNA expression, for-
ward primer 59-CAGCATCACTGGCC-AAGGAGCTGA-39
and reverse primer 59-GACCACACTGAT-GACTCCTGTG-
TTCC-39 were used. b-actin (forward primer: 59-TCACCCA-
CACTGT-GCCCATCTACGA-39, reverse primer 59-CAGCG-
GAACCGCT-CATTGCCAATGG-39) was used for normaliza-
tion. Reactions contained IQ Supermix (Bio-Rad), 6 pmol of each
primer, and 2 ml of cDNA in a total volume of 25 ml. PCR
conditions were 95uC for 90 s, followed by 40 cycles of 95uC for
15 s, 60uC (55uC for b-actin) for 20 s, and 72uC for 30 s. A
melting curve was obtained to verify specificity of the PCR.
In vivo tumor growth
All animal procedures were performed with approval from the
Peter MacCallum Cancer Centre animal experimentation ethics
committee. Control 4 or shRNA cells (3610
6) in 50% Matrigel
(Becton Dickinson) were implanted subcutaneously into the right
flank of 6–8 week old female Balb/c nude mice (Animal Resources
Centre, Western Australia). Once tumors were established, they
were measured twice weekly using electronic calipers and tumor
volume was calculated according to the formula: length/26
width
2. On harvest, the tumors were divided in half and one
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was fixed in formalin and embedded in paraffin. The snap frozen
samples were homogenized for assaying NAT1 activity or
sonicated in TRIzol reagent for RNA extraction. H&E and
immunochemical staining were performed on the paraffin
embedded samples.
Immunohistochemistry
Staining for Ki-67 was on 6 mm thick formalin-fixed, paraffin-
embedded tumor sections. After de-waxing, antigen retrieval was
performed with a 10 nM citrate buffer (pH 6.0) in a decloaking
chamber for 5 min at 125uC. Endogenous peroxidase activity was
inhibited using methanol and hydrogen peroxide. Immunohisto-
chemical staining was carried out using Vectastain ABC kit
(Vector Laboratories, Inc.). A MIB-1 monoclonal antibody (Dako,
Carpenteria, CA, USA) at a 1:100 dilution was used to probe
human ki-67 for 2 h at room temperature. Sites of peroxidase
activity were detected using 3,3-diaminobenzidine/hydrogen
peroxide. Counterstaining was performed with hematoxylin.
Data analysis
All experiments were performed in triplicate. Data are
expressed as mean 6 SEM. Statistical comparisons between
different groups were assessed by Student’s t test or one-way
ANOVA assuming significance at p,0.05 using Prism 4
(GraphPad Software, Inc., San Diego, CA, USA). Tumor growth
rates were compared by two-way ANOVA.
Results
NAT1 knock-down with shRNA altered cell growth and
survival
HT-29 cells were stably transfected with a shRNA expression
vector targeting NAT1 mRNA. Three independent clones were
selected and NAT1 activity was determined. In all three clones,
NAT1 activity was decreased by greater than 85% compared to
the non-transfected parental HT-29 cells or control cells
transfected with a scrambled shRNA sequence (Figure 1A).
Proliferation of the NAT1 knock-down cells with time was similar
to the control cells or non-transfected HT-29 cells during
exponential growth (Figure 1B). However, the NAT1 knock-down
cells reached a saturation density earlier than the control cells.
Following confluence at day 3, the number of NAT1 knock-down
cells in culture declined and this was associated with an increase in
cell death (Figure 1C). For the control cells, saturation density was
not reached until approximately day 5.
NAT1 knock-down with shRNA led to morphological
changes
At sub-confluent density, both the control and NAT1 knock-
down cells grew as monolayers and demonstrated a typical
epithelial morphology (Figure 2A, upper panels). Actin filaments
were generally unorganized and mostly associated with the sub-
cortical cytoskeleton (Figure 2B, upper panels). Transmission
electron microscopy also showed a similar morphology between
the control and knock-down cells at low density (Figure 2C, upper
panels). At high density, control cells exhibited multi-layer growth
characteristics (Figure 2A, lower panels), which was also evident by
transmission electron microscopy of confluent cells processed for
viewing in the longitudinal plane (Figure 2D, upper panel). Unlike
cells at low density, actin was mostly associated with intracellular
stress fibers at high density (Figure 2B, lower panels). The control
cells were highly vacuolated with vesicles that accumulated
towards one end of the cell (Figure 2C, lower left panel, arrows),
possibly indicative of cell polarization [17]. By contrast, the NAT1
knock-down cells maintained a monolayer at high density
(Figure 2A and D, lower panels). The cells were larger and more
cobble-shaped (Figure 2C, lower right panel). Actin stress fibers
were seen in all cells and polymerized actin remained associated
with the sub-cortical cytoskeleton and near sites of cell-cell contact
(Figure 2B, lower right panel, arrows). Under transmission
electron microscopy, very few intracellular vacuoles were seen in
the knock-down cells (Figure 2C, lower right panel). These results
indicate that loss of NAT1 is associated with a marked change in
cell morphology.
Loss of NAT1 inhibited anchorage-independent growth
and up-regulated E-cadherin protein expression
The ability for HT-29 cells to grow as multilayer cultures has
been associated with anchorage-independent growth [18]. To test
if NAT1 knock-down affected this, we examined colony formation
of control and knock-down cells in soft agar (Figure 3A).
Compared to cells treated with shRNA, the control cells formed
large colonies clearly visible to the eye. Colony count showed a
significantly greater number of colonies for the control cells
(Figure 3B), although the difference was only approximately 20%.
A much greater difference was seen when the size of the colonies
was quantified (Figure 3C). The control cells showed a wide
distribution in diameter ranging from 0.04 to 0.6 mm
(0.1760.03 mm) whereas the diameter of the NAT1 knock-down
cell colonies was much smaller (0.0860.004 mm), as was the range
(0.06–0.13 mm). These results, along with the lower saturation
density seen in Figure 1B, are consistent with cell-cell contact
inhibition of growth.
E-cadherin is a key protein involved in cell adhesion and
reportedly dictates responsiveness to contact inhibition in many
cancer cell-types [19]. We therefore examined the expression of E-
cadherin following NAT1 knock-down. E-cadherin protein
expression increased in the knock-down cells compared to the
control cells (Figure 3D). The increased E-cadherin expression was
primarily associated with the plasma membrane in the knock-
down cells (Figure 3E). These results show that NAT1 knock-down
restores cell contact inhibition in HT-29 cells, which could explain
the lower saturation density seen in the growth curves (Figure 1B).
The restoration of contact inhibition is possibly due to increased E-
cadherin expression.
Loss of NAT1 up-regulated E-cadherin mRNA
Quantification of E-cadherin mRNA revealed that up-regula-
tion of E-cadherin protein following NAT1 knock-down was
accompanied by an increase in E-cadherin mRNA (Figure 4A),
which was 2.5-fold higher in the shRNA3.2 cells. We measured
the expression level of the E-cadherin transcriptional repressors
Snail, Slug, and Twist (Figure 4B). There was no evidence of Slug
or Twist expression in either cell line, and Snail showed no change
following NAT1 knock-down. The results suggest that the
increased E-cadherin mRNA expression is independent of the
transcription repressors. E-cadherin can be regulated at transcrip-
tional and/or epigenetic levels [20]. Further studies are required to
determine if the change in E-cadherin expression is due to altered
DNA methylation status of the cells.
The up-regulation of E-cadherin by NAT1 shRNA was not
due to off-target effects
While shRNA-mediated gene silencing is highly sequence
specific, off-target effects are not uncommon [21]. To determine
NAT1 Knock-Down Up-Regulates E-cadherin
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other unidentified transcripts, two experiments were performed.
Firstly, NAT1 was reintroduced into the NAT1 knock-down cells
using a plasmid with the NAT1 gene under the control of the
CMV promoter to induce strong gene expression. NAT1 activity
was restored to a level greater than that seen in the parental HT-
29 cells (Figure 5A). Rescue of the NAT1 reversed the up-
regulation of E-cadherin in the knock-down cells (Figure 5B). To
ensure that the re-introduction of NAT1 did not switch off
expression of the shRNA, endogenous NAT1 mRNA was
quantified by amplification of exon 4, an exon located in the
59UTR of NAT1 mRNA but is absent in the plasmid used to
rescue NAT1 activity. Endogenous NAT1 mRNA remained low
and similar to that in the knock-down cells following reintroduc-
tion of the gene (Figure 5C), indicating that these cells were
actively expressing both the shRNA and exogenously introduced
NAT1.
In a second experiment, two additional non-overlapping
independent shRNA sequences targeting the NAT1 open reading
frame were used to silence NAT1 expression. All three shRNA
sequences significantly decreased NAT1 activity (Figure 5D). In
addition, all three sequences increased E-cadherin expression
(Figure 5E). Taken together, these results indicate that the effects
of NAT1 knock-down on E-cadherin expression are unlikely to be
due to off-target effects.
E-cadherin up-regulation was not confined to HT-29 cells
HT-29 cells are derived from a human colon adenocarcinoma
that has a large deletion at 8p21, the site of the NAT1 gene. In
addition, it has mutant p53 and truncated APC genes. To ensure
our observations following NAT1 silencing were independent of
the cell line, we generated stably transfected shRNA lines using the
prostate cell line 22Rv1. These cells are also epithelial but have
normal functioning p53 and APC. We selected 2 clones that
Figure 1. NAT1 knock-down alters cell growth and survival in HT-29 cells. (A) NAT1 activity in HT-29 cells and cells stably transfected with a
scrambled shRNA (Control 2 and Control 4) or NAT1-directed shRNA (shRNA 3.1, shRNA 3.2 and shRNA 3.8). Results are presented as mean 6 SEM
(n=3). Asterisks denote significant difference compared to HT-29 (p,0.05). (B) Growth of HT-29 shRNA clones. All clones were grown in RPMI 1640
supplemented with 5% FCS. Each point is the mean 6 SEM (n=3). (C) Viability of control cells (clone Control 4) and knock-down cells (clone shRNA
3.2) at day 4. Non-viable cells were stained with propidium iodide (PI) and quantified by flow cytometry. The reported percent viable and non-viable
cells are shown as the mean 6 SEM (n=3).
doi:10.1371/journal.pone.0017031.g001
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each clone, E-cadherin expression was increased compared to
control cells stably transfected with a scrambled sequence
(Figure 6B). Up-regulation of E-cadherin was also observed in
these cells by immunocytochemistry where the majority of the
protein was associated with the plasma membrane (Figure 6C).
These results showed that up-regulation of E-cadherin following
NAT1 knock-down was not confined to HT-29 cells.
NAT1 knock-down affected tumor growth in vivo
To evaluate the effect of NAT1 knock-down on tumor growth in
vivo, nude mice were injected subcutaneously with parental HT-29,
Control 4 or shRNA 3.2 cells and tumor development monitored
over 50 days (Figure 7A). Both the HT-29 and the control cells
grew at the same rate in vivo with an estimated doubling time of
10.7 days (95% CI =10.6–11.0). Two-way analysis of variance
showed that the shRNA growth curve was significantly different to
either the parent HT-29 cells or the Control 4 cells (p,0.05). This
was due to a modest but significant increase in the doubling time
of the shRNA cells to 12.1 days (95% CI =11.9–12.2). At the end
of the study, tumor tissue was collected for histological analysis and
enzyme activity measurements. Histologically, the adenocarcino-
mas from the Control 4 cells contained large areas of necrosis
surrounded by neoplastic columnar cells with a loose organization
(Figure 7B, top left panel). The shRNA 3.2 cells formed similar
adenocarcinomas containing mostly necrotic areas surrounded by
columnar cells. However, these tumors also contained well-
organized glandular bodies suggestive of a more differentiated
state (Figure 7B, top right panel). Immunohistochemistry of the
neoplastic columnar cells using an anti-Ki67 antibody to detect
proliferating cells showed little difference between the Control 4
tumors and the shRNA tumors (Figure 7B, middle panels).
However, the glandular tissue in the shRNA tumors contained
large tracts of non-proliferative cells (Figure 7B, lower panel).
NAT1 activity was 30% lower in the NAT1 knock-down tumors
compared to the control tumors (4.3960.27 and 6.346
0.31 nmol/min/mg protein, respectively; Figure 7C), which is
less than the 85% decrease seen in the shRNA 3.2 cells in culture
(Figure 1A). This difference between the in vitro and in vivo NAT1
activities could be due to the presence of mouse cell infiltrates in
the tumor samples, which express arylamine N-acetyltransferase.
However, the H&E staining and the immunohistochemistry,
which used a human-specific anti-Ki67 antibody, indicated that
there was little evidence for excessive infiltration of mouse cells in
the xenografts. An alternative explanation for the loss of NAT1
knock-down in vivo is the lack of selection with G418 during the in
vivo study. If this were the case, then the level of human NAT1
mRNA in the knock-down tumors would approach that in the
control tumors. We extracted total RNA from the tumor tissue and
quantified human NAT1 mRNA using specific primers that did
not amplify the mouse NAT homolog (Figure 7D). The relative
amount of human NAT1 mRNA was variable between samples
and was not significantly different between the 2 groups. (p=0.08).
These results suggest that the knock-down of NAT1 was not
maintained in HT-29 cells grown in vivo, where there was no G418
selection. Nevertheless, the growth of the NAT1 knock-down cells
was attenuated, indicating that NAT1 may have a role in tumor
cell growth and/or survival in vivo.
Discussion
When NAT1 was found to be involved in the metabolism of the
folate catabolite p-aminobenzoylglutamate, it was hypothesized
Figure 2. The effects of NAT1 knock-down on cell morphology. (A) Light microscopy of control (Control 4) and knock-down (shRNA 3.2) cells
at low density (upper panels) and high density (lower panels). (B) Confocal microscopy of actin polymerization in cells at low (upper panels) and high
(lower panels) density. Actin was stained with Alexa Fluor 647 conjugated phalloidin (red) and the cell nuclei were stained with DAPI (blue). White
arrows show sub-cortical actin associated with sites of cell-cell contact (lower right panel). (C) Transmission electron microscopy of control and NAT1
knock-down cells at low and high density. Black arrows show vacuoles. (D) Longitudinal sections of control and NAT1 knock-down cells by
transmission electron microscopy at high density. Arrowheads indicate the bottom of the culture flask.
doi:10.1371/journal.pone.0017031.g002
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(A) Colony formation of control (Control 4) and NAT1 knock-down cells (shRNA 3.2) in soft agar. Cells were seeded at 1,500 cells/ml on 0.6% agar and
grownfor10-14days.Colonies werevisualized with0.005%crystal violet. (B)Colonynumbers were determinedfrom3 independentsoft agar plates and
arepresentedas mean 6 SEM. Asterisk denotes significant difference compared to Control 4 (p,0.05). (C) Colony size(diameter) distributionfor control
and knock-down cells. (D) Western blot analysis of E-cadherin in control and NAT1 knock-down cells. Immunoblotting was performed with E-cadherin
antibody and tubulin was probed as the loading control. The blot is representative of three independent experiments. (E) Immunocytochemistry of E-
cadherin expression in control and NAT1 knock-down cells. The increased E-cadherin protein expression was localized to the cell membrane (white
arrows) in the NAT1 knock-down cells compared to control cells. E-cadherin was detected with anti-E-cadherin antibody followed by Alexa Fluor 488-
conjugated secondary antibody (green) and visualized under a fluorescence confocal microscope. The nuclei were stained with DAPI (blue).
doi:10.1371/journal.pone.0017031.g003
Figure 4. NAT1 knock-down up-regulates E-cadherin mRNA and alters DNA methylation status in the cell. (A) E-cadherin mRNA levels
in NAT1 knock-down cells. Each value is mean 6 SEM (n=3). The asterisk denotes significant difference from control (p,0.05). (B) Western blot
analysis of E-cadherin suppressor proteins in control and NAT1 knock-down cells. Twist and Slug were not detected in either cell-line and there was
no difference in the expression of Snail. Tubulin was probed as the loading control.
doi:10.1371/journal.pone.0017031.g004
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addition to acetylation of xenobiotics [3]. Mouse gene knockout
models of NAT1 (Nat2 or muNat2) have been developed
independently in 2 laboratories [22,23]. However, while acetyla-
tion of p-aminobenzoylglutamate was compromised, the animals
were healthy and largely indistinguishable from control litter-
mates. Several minor phenotypic changes in animals from one
laboratory were reported but they were not present in the animals
from the other laboratory. These animal models suggested that
NAT1 was not required for normal development and survival, at
least in the mouse, and did not point to any essential function for
the protein.
Figure 5. The effects of NAT1 knock-down by shRNA are not due to off-target effects. (A) NAT1 was reintroduced into the shRNA 3.2 cells
(shRNA 3.2+NAT1) and NAT1 activity measured. Each value is mean 6 SEM (n=3). The asterisk denotes a significant difference compared to Control 4
(p,0.05). (B) Control 4, shRNA3.2, and shRNA3.2+NAT1 cell lysates were immunoblotted for E-cadherin. Tubulin was probed as the loading control.
The blot is representative of 3 independent experiments. (C) NAT1 mRNA levels were quantified by real-time PCR using primers that detect
endogenous NAT1 mRNA but not NAT1 mRNA derived from the exogenous plasmid. The data are presented as mean 6 SEM (n=3). Results were
normalized to b-actin levels and then expressed relative to Control 4 mRNA. Asterisks denote significant difference compared to Control 4 (p,0.05).
(D) Different independent non-overlapping shRNA targeting the NAT1 open reading frame were used to knock-down NAT1 and then NAT1 activity
was assessed for each of the different clones. Each value is mean 6 SEM (n=3). Asterisks denote significant difference compared to Control 4
(p,0.05). (E) The effect of NAT1 knock-down by the different shRNA sequences on E-cadherin protein expression was determined by
immunoblotting. Tubulin was probed as the loading control.
doi:10.1371/journal.pone.0017031.g005
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showed a severephenotype, with most animals notsurviving to term
[24]. Those that did survive had NAT1 activities that were only
slightly higher than endogenous levels, suggesting that there is a
strong selection process during fetal development for high NAT1
activity and points towards a need for NAT1 gene regulation in vivo.
While mice can survive without the protein, they do not appear to
tolerate its over-expression. This is an interesting observation that
led us to examine the phenotypic changes induced in cancer cells
with altered expression of the NAT1 protein.
We have shown that NAT1 knock-down inhibits cell prolifer-
ation by lowering the growth saturation density, which was
accompanied by a decrease in cell viability. Morphological
changes, anchorage-independent growth and E-cadherin expres-
sion supported speculation that NAT1 knock-down alters cell-cell
contact inhibition. Our data indicated that off-target gene
silencing is unlikely to account for the phenotypic changes. We
also showed that up-regulation of E-cadherin was not confined to
the HT-29 cell line. Up-regulation of E-cadherin mRNA
suggested that NAT1 knock-down increased E-cadherin transcrip-
tion, possibly by a change in DNA methylation status of the cells
since levels of the transcriptional repressors Snail, Slug and Twist
were not altered.
Loss of contact inhibition is a common trait in cancer [25] and
restoration of this function is associated with expression of a family
of growth-arrest-specific genes [26]. Cam and coworkers showed
Figure 6. Up-regulation of E-cadherin following NAT1 knock-down is not cell-type specific. (A) 22Rv1 cells were stably transfected with
the NAT1-directed shRNA construct (Clones 1 and 2) and knock-down determined by NAT1 activity assay. Results are presented as mean 6 SEM
(n=3). Asterisks denote significant difference compared to the control (p,0.05). (B) Western blot analysis of E-cadherin protein in 22Rv1 control and
NAT1 knock-down cells. Immunoblotting was performed with E-cadherin antibody and tubulin was probed as the loading control. The blot is
representative of 3 independent experiments. Immunoblots were quantified by densitometry after normalization to tubulin. Results are presented as
means 6 SEM (n=3). A representative blot is shown above the graph. Asterisks denote significant difference compared to control (P,0.05). (C)
Immunocytochemistry of E-cadherin expression in 22Rv1 control and NAT1 knock-down cells. E-cadherin was detected with anti-E-cadherin antibody
followed by Alexa Fluor 488-conjugated secondary antibody (green) and visualized under a fluorescence microscope. The nuclei were stained with
DAPI (blue).
doi:10.1371/journal.pone.0017031.g006
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following growth arrest induced by contact inhibition [27].
Moreover, when NAT1 was over-expressed in HB4a cells, they
showed continued proliferation at cell densities where normal
HB4a cell growth reached a plateau [8]. These observations
support our current results that demonstrate a relationship
between NAT1 expression and the ability for cells to undergo
growth arrest. E-cadherin is believed to be beneficial in cancer
treatment as this multi-faceted tumor suppressor protein is
involved in many aspects of cancer biology including cell contact
inhibition [28,29,30]. Experimental and clinical studies are in
agreement that loss of E-cadherin is strongly associated with poor
disease survivals [31,32,33,34,35,36].
NAT1 knock-down significantly slowed tumor formation in vivo,
although the effect was only marginal. This may, in part, be due to
the loss of shRNA function in vivo since both NAT1 activity and
mRNA levels were not suppressed to the same level as that
observed in vitro. The tumors formed from cells with NAT1 knock-
down appeared more differentiated suggesting that some pheno-
typic changes may remain in vivo. Nevertheless, others have shown
that up-regulation of E-cadherin in cancer cells still allows tumor
formation, albeit at a slower rate [37]. Perhaps of greater interest is
the general loss of metastatic potential in cells that express E-
cadherin [38]. This was not investigated in the present study
because HT-29 cells do not readily metastasize in the nude mouse
model following subcutaneous administration. We are currently
investigating the effect of NAT1 knock-down in MDA-MB-231, a
highly metastatic breast cancer cell line, in nude mice.
NAT1 catalyses the acetylation of arylamines via a cysteine-
histidine-aspartic acid catalytic triad similar to that found in the
Figure 7. Growth of control and NAT1 knock-down cells in vivo. (A) Female Balb/c nude mice were injected subcutaneously with parental HT-
29 cells (e), Control 4 cells (N), or shRNA3.2 cells (#). Tumor volume was determined as outlined in the Methods. Results are mean 6 SEM (n=7–8).
(B) Representative H&E staining of tumors (upper panels) from Control 4 (left panel) or shRNA 3.2 (right panel) showing large areas of necrosis (*)
along with loosely organized columnar cells (small arrows). In the tumors derived from the shRNA 3.2 cells, more organized glandular structures were
evident (large arrow). Representative immunohistochemistry for Ki67 in Control 4 and shRNA 3.2 tumors is shown in the middle and lower panels. (C)
NAT1 activity in individual tumors from Control 4 and shRNA3.2 tumor tissue. The results are mean 6 SEM (n=3). (D) Real-time PCR of human NAT1
mRNA in individual tumors from Control 4 and shRNA3.2 tumor tissues. Results were normalized to b-actin and then expressed relative to Control 4.
The results are mean 6 SEM (n=3).
doi:10.1371/journal.pone.0017031.g007
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has also been implicated in the stability of NAT1 [5]. It remains
unclear whether the NAT1 acetylating capacity is responsible for
the observed phenotypic changes in the present study, or whether
other mechanisms, such as protein-protein interaction, could
account for these changes. We attempted to address this question
by re-introducing a cysteine mutant of NAT1, which is
catalytically inactive, into the shRNA 3.2 cells to rescue the
phenotype. However, we were unable to isolate clones that
expressed increased levels of NAT1 protein, possibly due to the
instability of the mutant protein which is rapidly poly-ubiquiti-
nated [5].
In conclusion, the current study has identified a phenotypic
change in cancer cells associated with the loss of NAT1 protein. It
shows that NAT1 may function beyond a Phase II xenobiotic
metabolizing enzyme and raises the possibility that it is a potential
therapeutic target in cancer. Further studies are required to map
out the molecular mechanism underlying the cellular changes
following NAT1 knock-down.
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